Evofem Press

Wainwright & Co. Evofem Biosciences stock price prediction is an act of determining the future value of Evofem Biosciences shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. SAN DIEGO, March 24, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Rarick is a board-certified. Press Releases Press Releases Year 2018 2019 2020 2021 Submit. 27 per share on revenue of $1. Common Stock (EVFM) Nasdaq Listed. Evofem Biosciences General Information Description. Evofem presented at a conference for investors, and it went well enough that by the spring of 2016, Pelletier had the company on a roadshow to raise $200 million in an IPO. Data is currently not available. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. Evofem Biosciences Announces U. 2 days ago · McCann Health New Jersey is launching a new campaign for Evofem Biosciences Inc. 86% of Evofem Biosciences' shares are currently sold short. PR Newswire. San Diego-based Evofem Biosciences, a developer of biopharmaceuticals for female reproductive health, reported it raised $50M in its previously announced public offering. Research Reports. View today's stock price, news and analysis for Evofem Biosciences Inc. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. See full list on fool. , (NASDAQ:EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. You should receive confirmation of this transaction. is a commercial-stage biopharmaceutical company. com/picks_monster Join the Discord chat: https://discord. Evofem Biosciences' stock was trading at $5. About Evofem Biosciences Evofem Biosciences, Inc. SAN DIEGO, July 14, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Press Releases. This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as, statements related to the consummation of the proposed public offering, intended use of proceeds, the potential terms of the offering and Evofem's expectations with respect to. Evofem Biosciences, Inc. DUBLIN--(BUSINESS WIRE)--Aug 31, 2021--The "Chlamydia Infections (Infectious Disease) - Drugs In Development, 2021" report has been added to ResearchAndMarkets. (EVFM) develops and commercializes various products to address needs in women's sexual and reproductive health. Phone Number +858. Phexxi comes in an applicator that women insert before sex. Evofem Biosciences, Inc. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update. Investor Relations Contact Amy Raskopf Evofem Biosciences, Inc. Common Stock (EVFM) Nasdaq Listed. SAN DIEGO, Sept. EVOFEM JUST LAUNCHED THE WORLD'S FIRST NON-HORMONAL BIRTH CONTROL! Q1 SALES REPORT THIS MONTH GET IN THIS NOW. 2 days ago · Evofem Biosciences, Inc. Evofem’s mission is to empower women by providing products that give women the control and flexibility they desire. PR Newswire. Press down arrow for suggestions, or Escape to return to entry field. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update PR Newswire - PRF - Wed Aug 11, 3:27PM CDT /PRNewswire/ -- Evofem Biosciences, Inc. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to Evofem Biosciences' expectations regarding the success and timing of commercial launch and availability of Phexxi, the. Short interest is the volume of Evofem Biosciences shares that have been sold short but have not yet been covered or closed out. SAN DIEGO , May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Company Type For Profit. , which closed January 17, 2018. Evofem Biosciences, Inc. 27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0. 12400 High Bluff Drive, Suite 600 San Diego, California 92130 1. It addresses women's unmet medical needs through the discovery, development and commercialization of healthcare products. [email protected] (NASDAQ: EVFM) today announced the pricing of its previously announced underwritten public offering of 50,000,000 shares of its common stock and accompanying short-term warrants to purchase up to an aggregate of 50,000,000 shares of common stock. 50 (does not reflect net pricing to Evofem) 347 763. elementor-2987. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. Please fill out the form below for media inquiries about Evofem Biosciences. Evofem Biosciences. Phone Number +858. This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the. 2 days ago · SAN DIEGO, Sept. Fulfilling a critical unmet need in the contraceptive space, Phexxi. Evofem intends to use the net proceeds from the offering for the continuation of full This press release does not constitute an offer to sell or a solicitation of an offer to buy these. 5, an environment that is inhospitable to sperm, Evofem Biosciences. Chlamydia is a sexually transmitted infection caused by a bacterium. Press Release Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual. , today announced the company will deliver the keynote address and present two poster presentations on Phexxi ® at the upcoming NCODA 2021 National Spring Forum, which. Chlamydia Infections - Drugs In Development, 2021, provides an overview of the pipeline landscape. issued a press release announcing its financial results for the three months ended March 31, 2021. (NASDAQ: EVFM) marketingsentinel 8/6. Nasdaq 100. SAN DIEGO, Sept. Evofem Biosciences General Information Description. Press Release Evofem Biosciences, Inc. Contact Email [email protected] Research Reports. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. Evofem Biosciences is a biotech company that develops and markets a variety of products to meet women's sexual and reproductive health needs. Full Name *. Shares of Evofem Biosciences (NASDAQ: EVFM) are down by 20. This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as, statements related to the. Evofem Biosciences, Inc. SAN DIEGO , May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Stock Symbol NASDAQ:EVFM. PR Newswire - 11:02 PM ET 05/17/2021. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. Tuesday to discuss the FDA approval. SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to Evofem Biosciences' expectations regarding the success and timing of commercial launch and availability of Phexxi, the. Press Releases. Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. 2 days ago · Evofem Biosciences, Inc. On August 11, 2021, Evofem Biosciences, Inc. Evofem Biosciences, Inc. By PR Newswire. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. Nasdaq 100. 45% of gains in the last five trading sessions. Press Releases. As of July 15th, investors have sold 28,070,000 shares of EVFM short. Evofem Biosciences, Inc. The press release is attached as Exhibit 99. The financing's first closing on April 24, 2020 provided Evofem with $15 million of up to $25 million in convertible notes. Its main product is Phexxi, which is a vaginal gel to prevent pregnancy. Evofem became a public company through a reverse merger with Neothetics, Inc. 8/4/2020 8:00:00 AM Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update (Press Release) 8/4/2020 6:12:02 AM Pre-market Movers In Healthcare Sector: ATHE, COCP, CHFS, EVFM, DBVT. Evofem presented at a conference for investors, and it went well enough that by the spring of 2016, Pelletier had the company on a roadshow to raise $200 million in an IPO. EVOFEM BIOSCIENCES, INC. 9M misses by $0. •Full press day with celebrity in NYC Gross value of Phexxi user = $267. On May 17, 2021, Evofem Biosciences, Inc. Evofem Biosciences Announces Pricing of $50 Million Public Offering. ( EVFM ), today reported financial results for the three- and six-month periods ended June 30, 2021. Investor relations | Nasdaq: EVFM | Nasdaq. The average stock price target is $4. [email protected] : Press releases relating to EVOFEM BIOSCIENCES, INC. Evofem Biosciences stock price prediction is an act of determining the future value of Evofem Biosciences shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. Since Morgan Stanley isn't in the business of lighting money on fire, we can assume they did their due diligence on this one. Stock Symbol NASDAQ:EVFM. , today announced the company will deliver the keynote address and present two poster presentations on Phexxi ® at the upcoming NCODA 2021 National Spring Forum, which. 50 WAC x 7 annual refills = $1,872. SAN DIEGO, July 14, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi® Annie Murphy. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. The company sold 50 million. Investor Relations Contact Amy Raskopf Evofem Biosciences, Inc. 's revolutionary hormone-free birth control product, Phexxi. Investor Contact Amy Raskopf Evofem Biosciences, Inc. Evofem Biosciences, Inc. 12400 High Bluff Drive, Suite 600 San Diego, California 92130 1. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). Evofem Biosciences, Inc. com Mobile: (718) 490. Evofem Biosciences (EVFM) reported a 2nd Quarter June 2021 loss of $0. Evofem Biosciences is selling for 0. (Evofem's stock is trading for about $1 now; its high in the last year was $4. 56) earnings per share over the last year (($1. 01 by reference. , a clinical-stage biopharmaceutical company, today announced the appointment of Lisa Rarick, M. By PR Newswire. elementor-element-67dff9f >. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free,. 5, an environment that is inhospitable to sperm, Evofem Biosciences. Sayana Press. , today announced the company will deliver the keynote address and present two poster presentations on Phexxi ® at the upcoming NCODA 2021 National Spring Forum, which. 50 (does not reflect net pricing to Evofem) 347 763. com Mobile: (718) 490-3248. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. 27% from its latest closing price compared to the recent 1-year high of $17. SAN DIEGO, Sept. EVFM stock is greatly undervalued. Launched in 2020, FDA-approved Phexxi ® (lactic acid, citric acid and potassium bitartrate) vaginal gel is a first-in-class hormone-free, on-demand prescription contraception that a woman can control. The Outcome. About Evofem Biosciences Evofem Biosciences, Inc. Evofem Biosciences, Inc. (NASDAQ: EVFM) has recruited Emmy Award-winning “Schitt’s Creek” actress Annie Murphy to star in a new marketing campaign for its Phexxi hormone-free contraceptive. , (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30. 0 million at June 30, 2021. 01 by reference. Use historical and current headlines to determine the investment entry and exit points. 2 days ago · Evofem Biosciences, Inc. [email protected] Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. Nasdaq 100. 1% (13 million-ish) stake in Evofem. Evofem Biosciences Inc. elementor-element. View today's stock price, news and analysis for Evofem Biosciences Inc. , which closed January 17, 2018. Press Release Cash and cash equivalents was $47. About Evofem Biosciences Evofem Biosciences, Inc. View today's stock price, news and analysis for Evofem Biosciences Inc. 56) earnings per share over the last year (($1. Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. issued a press release announcing its financial results for the three and six months ended June 30, 2021. [email protected] The company’s stock price has collected 12. Evofem Biosciences, Inc. - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -. elementor-element-67dff9f >. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Wainwright & Co. PR Newswire. FDA in May 2020. But Phexxi works differently. 0 million at June 30, 2021. com and filed with the Securities Exchange Commission as additional proxy materials, and as otherwise required by applicable state law. Its product, Phexxi, which is a pregnancy prevention gel for women, was approved by the U. EVOFEM JUST LAUNCHED THE WORLD'S FIRST NON-HORMONAL BIRTH CONTROL! Q1 SALES REPORT THIS MONTH GET IN THIS NOW. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. Evofem Biosciences Inc. SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. commercial launch of Phexxi on September 8, 2020 as the first and only hormone-free, prescription. Evofem Biosciences, Inc. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. , (NASDAQ:EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. com - May 18 at 5:18 PM: Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount finance. The press release is attached as Exhibit 99. [email protected] com Mobile: (917) 673-5775. Press Release. Many technical investors use Evofem Biosciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free,. Chlamydia is a sexually transmitted infection caused by a bacterium. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to Evofem Biosciences' expectations regarding the success and timing of commercial launch and availability of Phexxi, the. Please fill out the form below for media inquiries about Evofem Biosciences. [email protected] Investor relations | Nasdaq: EVFM | Nasdaq. Evofem Biosciences, Inc. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. (NASDAQ: EVFM) today announced the pricing of its previously announced underwritten public offering of 50,000,000 shares of its common stock and accompanying short-term. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. You should receive confirmation of this transaction. Evofem Biosciences, Inc. 2 days ago · Evofem Biosciences, Inc. Other institutions have also been adding to their EVFM position. 0 million at June 30, 2021. About Evofem Biosciences Evofem Biosciences, Inc. Company profile page for Evofem Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information. The new gel has some similarities to spermicides, which block the entrance to the cervix and slow sperm down. 27 per share on revenue of $1. Press Release reported on 06/14/21 that Thinking about buying stock in Evofem Bi. Evofem Biosciences, Inc. Evofem Biosciences News. 1 to this Current Report on Form 8-K. issued a press release announcing its financial results for the three months ended March 31, 2021. --Evofem Biosciences, Inc. Evofem Biosciences has generated ($1. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to. Latest Press Releases Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update - PR Newswire - PRF - Wed Aug 11, 3:27PM CDT. 01 by reference. The company’s stock price has collected -6. Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. Sep 10, 2021 · MediaCo Holding Inc. Rarick is a board-certified. 2 days ago · Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a. Latest Press Releases Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update - PR Newswire - PRF - Wed Aug 11, 3:27PM CDT. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward. May 21, 2021 · Evofem Biosciences Raises $50M In Offering. , (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two. The average stock price target is $4. Stock Symbol NASDAQ:EVFM. Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. --Evofem Biosciences, Inc. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. Operating Status Active. You should receive confirmation of this transaction. 95% of loss in the last five trading sessions. : Press releases relating to EVOFEM BIOSCIENCES, INC. This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as, statements related to the consummation of the proposed public offering, intended use of proceeds, the potential terms of the offering and Evofem's expectations with respect to. A high-level overview of Evofem Biosciences, Inc. Results of Operations and Financial Condition. Evofem became a public company through a reverse merger with Neothetics, Inc. On August 11, 2021, Evofem Biosciences, Inc. Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi® Evofem Biosciences, Inc. Evofem Biosciences, Inc. Evofem Biosciences Announces U. The presentation will be webcast live and archived for 30 days thereafter. Press Release Cash and cash equivalents was $47. elementor-2987. Media contactsubmission form. Evofem Biosciences, Inc. The financing's first closing on April 24, 2020 provided Evofem with $15 million of up to $25 million in convertible notes. Since then, EVFM shares have decreased by 83. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a. Learn More on Evofem Biosciences' current short interest. com a copy of its current corporate slide presentation. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Evofem presented at a conference for investors, and it went well enough that by the spring of 2016, Pelletier had the company on a roadshow to raise $200 million in an IPO. In addition, Evofem granted the underwriter a 30-day option to purchase up to an. SAN DIEGO, Aug. The stock's lowest day price was 0. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. Phone Number +858. , today announced the company will deliver the keynote address and present two poster presentations on Phexxi ® at the upcoming NCODA 2021 National Spring Forum, which. com Mobile: (718) 490. Evofem Biosciences General Information Description. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a. ( EVFM ), today reported financial results for the three- and six-month periods ended June 30, 2021. ) Phexxi has a long way to go before profitability, and Evofem is testing a major second use for it, with high. Wainwright & Co. Launched in 2020, FDA-approved Phexxi ® (lactic acid, citric acid and potassium bitartrate) vaginal gel is a first-in-class hormone-free, on-demand prescription contraception that a woman can control. stocksregister 2 days ago. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). Company profile page for Evofem Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information. 8/4/2020 8:00:00 AM Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update (Press Release) 8/4/2020 6:12:02 AM Pre-market Movers In Healthcare Sector: ATHE, COCP, CHFS, EVFM, DBVT. This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as, statements related to the consummation of the proposed public offering, intended use of proceeds, the potential terms of the offering and Evofem's expectations with respect to. is a commercial-stage biopharmaceutical company. Evofem Biosciences, Inc. 12400 High Bluff Drive, Suite 600 San Diego, California 92130 1. (NASDAQ:MDIA) went up by 9. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). EVOFEM JUST LAUNCHED THE WORLD'S FIRST NON-HORMONAL BIRTH CONTROL! Q1 SALES REPORT THIS MONTH GET IN THIS NOW. Evofem Stock News module provides quick insight into current market opportunities from investing in Evofem Biosciences. Sep 09, 2021 · SAN DIEGO, Sept. Fulfilling a critical unmet need in the contraceptive space, Phexxi. EDT on Friday, after dropping by as much as 25. About Evofem Biosciences Evofem Biosciences, Inc. The new gel has some similarities to spermicides, which block the entrance to the cervix and slow sperm down. elementor-element-67dff9f >. Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $30. Also Known As Neothetics. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Welcome to the Evofem Biosciences' Q2 conference call. Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. Press Releases Press Releases Year 2018 2019 2020 2021 Submit. Its product, Phexxi, which is a pregnancy prevention gel for women, was approved by the U. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Evofem Biosciences, Inc. SAN DIEGO, July 14, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. PR Newswire - 11:02 PM ET 05/17/2021. com Mobile: (917) 673-5775 Media Contact Ellen Thomas Evofem Biosciences, Inc. Rarick is a board-certified. Common Stock (EVFM) Nasdaq Listed. 1 to this Current Report on Form 8-K. Evofem's mission is to empower women by providing products that give women the control and flexibility they desire. Evofem Biosciences has generated ($1. This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the. 11, 2021 Evofem Biosciences, Inc. 35 per share on revenue of $2. Evofem Biosciences last released its earnings data on August 10th, 2021. Fulfilling a critical unmet need in the contraceptive space, Phexxi. Sep 10, 2021 · MediaCo Holding Inc. Watch this video and make your own decision. "We are pleased to show strong and sustainable growth in Phexxi prescriptions and dispensed units. This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as, statements related to the consummation of the proposed public offering, intended use of proceeds, the potential terms of the offering and Evofem's expectations with respect to. Evofem Biosciences, Inc. SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. ResearchAndMarkets. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. The Company launched it’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in September 2020. A high-level overview of Evofem Biosciences, Inc. The successful prediction of Evofem Biosciences' future price could yield a significant profit. 8% and is now trading at $0. On March 25, 2020, the Company issued a press release announcing the adoption of the Rights Agreement and the declaration of the Rights dividend. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. SAN DIEGO, Sept. Evofem Biosciences (EVFM) reported a 2nd Quarter June 2021 loss of $0. Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. elementor-element. Evofem Biosciences, Inc. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update PR Newswire - PRF - Wed Aug 11, 3:27PM CDT /PRNewswire/ -- Evofem Biosciences, Inc. The company is also working on the development of EVO100, a vaginal gel for the prevention of Chlamydia infection and Neisseria gonorrhoeae infection in women. stocksregister 2 days ago. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a. Press Release; 06/21/21; Press Release; Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences? Press Release; 06/14/21; Press. May 21, 2021 · Evofem Biosciences Raises $50M In Offering. 27% from its latest closing price compared to the recent 1-year high of $17. FDA in May 2020. Its product, Phexxi, which is a pregnancy prevention gel for women, was approved by the U. Evofem Biosciences, Inc. Sayana Press. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2021. com - May 18 at 5:18 PM: Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount finance. Access information for quarterly and annual financial results calls and/or webcasts will be disclosed in a press release and included in the Events and Presentations section of our Investor Relations website. today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with H. Please fill out the form below for media inquiries about Evofem Biosciences. Mar 16, 2021 8:00 AM. (NASDAQ: EVFM): An Enticing Stock To Watch. issued a press release announcing its financial results for the three months ended March 31, 2021. Use historical and current headlines to determine the investment entry and exit points. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free,. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. 11, 2021 Evofem Biosciences, Inc. - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -. --Evofem Biosciences, Inc. Since Morgan Stanley isn't in the business of lighting money on fire, we can assume they did their due diligence on this one. Welcome to the Evofem Biosciences' Q2 conference call. 2 days ago · Evofem Biosciences, Inc. Evofem Biosciences Inc. 50 WAC x 7 annual refills = $1,872. elementor-element-67dff9f >. com) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). (NASDAQ:MDIA) went up by 9. SAN DIEGO, Sept. 94%) DATA AS OF Aug 31, 2021 2:02 PM ET. Company Type For Profit. 6M after underwriting discounts, commissions, and expenses. Research Reports. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. Evofem Biosciences. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. Evofem Biosciences, Inc. Aug 11, 2021 · Evofem Biosciences (NASDAQ:EVFM): Q2 GAAP EPS of -$0. Media Contact Ellen Thomas Evofem Biosciences, Inc. "We are pleased to show strong and sustainable growth in. com - May 18 at 12:17 PM: Evofem Biosciences Announces Proposed. Phexxi is a non-hormonal, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3. today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to. Press down arrow for suggestions, or Escape to return to entry field. Nasdaq 100. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation. , (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update. Sep 10, 2021 · MediaCo Holding Inc. Evofem Biosciences, San Diego, California. Assignment. Full Name *. Its main product is Phexxi, which is a vaginal gel to prevent pregnancy. ( EVFM ), today reported financial results for the three- and six-month periods ended June 30, 2021. --Evofem Biosciences, Inc. [email protected] Media Contact Ellen Thomas Evofem Biosciences, Inc. Media contactsubmission form. today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to. Evofem Biosciences, Inc. If we take this step, we will announce any changes in advance in a press release available on our website www. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). Wainwright & Co. Press Release; 06/21/21; Press Release; Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences? Press Release; 06/14/21; Press. Phexxi is a non-hormonal, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. com Mobile: (917) 673-5775 Media Contact Ellen Thomas Evofem Biosciences, Inc. EVOFEM JUST LAUNCHED THE WORLD'S FIRST NON-HORMONAL BIRTH CONTROL! Q1 SALES REPORT THIS MONTH GET IN THIS NOW. Evofem Biosciences is a biotech company that develops and markets a variety of products to meet women's sexual and reproductive health needs. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Full Name *. The Company launched it’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in September 2020. Sep 10, 2021 · MediaCo Holding Inc. Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact. , (NASDAQ: EVFM) today provided a preliminary look at Phexxi ® (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method. [email protected] (NASDAQ: EVFM) has recruited Emmy Award-winning “Schitt’s Creek” actress Annie Murphy to star in a new marketing campaign for its Phexxi hormone-free contraceptive. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). 4% earlier today. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a. 's revolutionary hormone-free birth control product, Phexxi. May 17, 2021 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support. 1 to this Current Report on Form 8-K. Research Reports. The financing's first closing on April 24, 2020 provided Evofem with $15 million of up to $25 million in convertible notes. Evofem Biosciences, Inc. Chlamydia is a sexually transmitted infection caused by a bacterium. 01 by reference. Phone Number +858. : Press releases relating to EVOFEM BIOSCIENCES, INC. 8% and is now trading at $0. Results of Operations and Financial Condition. Evofem Biosciences General Information Description. (NASDAQ:MDIA) went up by 9. 8/4/2020 8:00:00 AM Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update (Press Release) 8/4/2020 6:12:02 AM Pre-market Movers In Healthcare Sector: ATHE, COCP, CHFS, EVFM, DBVT. Learn More on Evofem Biosciences' current short interest. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. Evofem Biosciences, Inc. com Mobile: (718) 490. View today's stock price, news and analysis for Evofem Biosciences Inc. Evofem Biosciences last released its earnings data on August 10th, 2021. The list price for Phexxi will be $250 to $275 for a box of 12 without insurance, the company said. Evofem Biosciences, Inc. com's offering. Forward-Looking Statements This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as. 12400 High Bluff Drive, Suite 600 San Diego, California 92130 1. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. 6M after underwriting discounts, commissions, and expenses. In addition, Evofem granted the underwriter a 30-day option to purchase up to an. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with H. The company is also working on the development of EVO100, a vaginal gel for the prevention of Chlamydia infection and Neisseria gonorrhoeae infection in women. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. 95% of loss in the last five trading sessions. Wainwright & Co. (NASDAQ: EVFM) has recruited Emmy Award-winning “Schitt’s Creek” actress Annie Murphy to star in a new marketing campaign for its Phexxi hormone-free contraceptive. 94%) DATA AS OF Aug 31, 2021 2:02 PM ET. Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact. This Is A Time To Build A Position In Evofem Biosciences Inc. On August 11, 2021, Evofem Biosciences, Inc. Evofem Biosciences, Inc. 6% as of 11:43 a. Sep 10, 2021 · MediaCo Holding Inc. 86% of Evofem Biosciences' shares are currently sold short. com - May 18 at 12:17 PM: Evofem Biosciences Announces Proposed. PR Newswire. Phexxi is a non-hormonal, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3. Shares of Evofem Biosciences (NASDAQ: EVFM) are down by 20. Short interest is the volume of Evofem Biosciences shares that have been sold short but have not yet been covered or closed out. Press Release reported on 06/14/21 that Thinking about buying stock in Evofem Bi. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. 5, an environment that is inhospitable to sperm, Evofem Biosciences. Sep 10, 2021 · MediaCo Holding Inc. The new gel has some similarities to spermicides, which block the entrance to the cervix and slow sperm down. On March 25, 2020, the Company issued a press release announcing the adoption of the Rights Agreement and the declaration of the Rights dividend. commercial launch of Phexxi, our non-hormonal, on-demand birth control method," said. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. /CAN Toll Free Call 1-800-526-8630 For GMT Office. 1 to this Current Report on Form 8-K. Investor Relations Contact Amy Raskopf Evofem Biosciences, Inc. About Evofem Biosciences Evofem Biosciences, Inc. com - May 18 at 5:18 PM: Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount finance. Phone Number +858. Evofem Biosciences, Inc. Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $30. PR Newswire - 11:02 PM ET 05/17/2021. Evofem Biosciences Inc. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The gel made by San Diego-based Evofem Biosciences contains lactic acid, citric acid and potassium bitartrate, all of which are common food additives. Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also. To report an adverse event related to the use of Phexxi®, please call 1-833-EVFMBIO (1-833-383-6246. ResearchAndMarkets. commercial launch of Phexxi on September 8, 2020 as the first and only hormone-free, prescription. The press release is attached as Exhibit 99. Evofem Biosciences, Inc. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. com Mobile: (917) 673-5775 Media Contact Ellen Thomas Evofem Biosciences, Inc. Research Reports. 1% (13 million-ish) stake in Evofem. today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to. , (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). com) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). com Mobile: (718) 490-3248. OUT OF COMPLIANCE. 27 beats by $0. About Evofem Biosciences Evofem Biosciences, Inc. com - May 18 at 12:17 PM: Evofem Biosciences Announces Proposed. 6% as of 11:43 a. Evofem Biosciences, Inc. Evofem Biosciences, San Diego, California. 12400 High Bluff Drive, Suite 600 San Diego, California 92130 1. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. The consensus estimate was a loss of $0. com - May 18 at 5:18 PM: Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount finance. SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. com - May 18 at 12:17 PM: Evofem Biosciences Announces Proposed. DUBLIN--(BUSINESS WIRE)--Aug 31, 2021--The "Chlamydia Infections (Infectious Disease) - Drugs In Development, 2021" report has been added to ResearchAndMarkets. Use historical and current headlines to determine the investment entry and exit points. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. Evofem Biosciences Announces Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention. Wainwright & Co. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. On May 6, 2021, Evofem Biosciences, Inc. Phone Number +858. The stock's lowest day price was 0. commercial launch of Phexxi on September 8, 2020 as the first and only hormone-free, prescription. Its product, Phexxi, which is a pregnancy prevention gel for women, was approved by the U. 11, 2021 Evofem Biosciences, Inc. Shares of Evofem Biosciences (NASDAQ: EVFM) are down by 20. The latest tweets from @evofem. About Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a. Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. May 21, 2021 · Evofem Biosciences Raises $50M In Offering. issued a press release announcing its financial results for the three months ended March 31, 2021. Evofem Biosciences, Inc. , (NASDAQ:EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and. ResearchAndMarkets. Sayana Press. is a commercial-stage biopharmaceutical company. com Mobile: (718) 490-3248. , (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two. Forward-Looking Statements This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as. com - May 21 at 9:16 AM: Why Evofem Biosciences' Stock Is Trading Lower Today msn. Phexxi is a non-hormonal, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3. T Office Hours Call 1-917-300-0470 For U. Evofem Biosciences last released its earnings data on August 10th, 2021. On May 17, 2021, Evofem Biosciences, Inc. By PR Newswire. Research Reports. OUT OF COMPLIANCE. Get the latest Evofem Biosciences Inc (EVFM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Operating Status Active. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the. Forward-Looking Statements This press release includes "forward-looking statements," including without limitation statements related to the proposed public offering of securities by Evofem such as. Following Evofem's PDUFA date of May 25, 2020, Mintz expects to assist Evofem as it embarks on a much larger equity financing to fully fund the launch and commercialization of its lead product, a non. SAN DIEGO, Aug. Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021. Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update. Mar 16, 2021 8:00 AM. Evofem Biosciences, Inc.